The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...
In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.